Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results symbols : Chrs save search
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Published: 2024-03-13 (Crawled : 20:00) - globenewswire.com
ABBV | News | $165.09 0.26% 760K
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: -8.7%
H: 21.43%
C: 3.33%
business year update financial
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Published: 2024-03-06 (Crawled : 21:00) - prnewswire.com
INO 3 d | $9.98 -2.16% 50K
|
Health Technology
|
| O: -2.23%
H: 0.62%
C: -6.42%
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: 0.45%
H: 1.13%
C: -0.45%
year financial results
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: 2.29%
H: 4.04%
C: -0.9%
report year financial results
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
Published: 2023-11-28 (Crawled : 16:00) - globenewswire.com
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: -1.55%
H: 12.83%
C: 10.47%
piter-02 association positive publication treatment medical trial results
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
VCNX | $4.8 770
|
Health Technology
|
| O: 2.76%
H: 1.08%
C: -3.23%
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: 0.63%
H: 8.12%
C: 7.5%
update financial results
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
ABBV | News | $165.09 0.26% 760K
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: -22.6%
H: 3.28%
C: -9.85%
business financial results
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
Published: 2023-10-30 (Crawled : 22:00) - globenewswire.com
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: -5.32%
H: 19.65%
C: 17.54%
report financial results
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-08-14 (Crawled : 12:00) - ir.vaccinex.com
VCNX | $4.8 770
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: -8.08%
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: -1.99%
H: 0.21%
C: -3.0%
update financial results
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
Published: 2023-08-02 (Crawled : 20:00) - globenewswire.com
ABBV | News | $165.09 0.26% 760K
|
Health Technology
|
| O: -0.28%
H: 0.27%
C: 0.06%
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: 3.49%
H: 14.13%
C: 10.87%
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: 9.45%
H: 10.53%
C: 7.58%
business financial results
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
Published: 2023-07-26 (Crawled : 20:00) - globenewswire.com
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: 1.55%
H: 2.83%
C: 0.0%
report financial results
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Published: 2023-06-05 (Crawled : 22:00) - globenewswire.com
ABBV | News | $165.09 0.26% 760K
|
Health Technology
|
| O: 0.45%
H: 0.05%
C: -1.48%
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: 0.4%
H: 9.6%
C: 5.4%
piter-02 positive trial results
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
Published: 2023-05-08 (Crawled : 20:00) - globenewswire.com
ABBV | News | $165.09 0.26% 760K
|
Health Technology
|
| O: -0.03%
H: 0.71%
C: -0.39%
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: -20.64%
H: 0.93%
C: -8.51%
business financial results
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
Published: 2023-05-01 (Crawled : 20:00) - globenewswire.com
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: -0.65%
H: 0.79%
C: -5.91%
report financial results
Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates
Published: 2023-03-31 (Crawled : 09:00) - globenewswire.com
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: 1.24%
H: 5.38%
C: 5.07%
year financial results
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
Published: 2023-03-06 (Crawled : 21:00) - globenewswire.com
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: -3.55%
H: 12.33%
C: 11.79%
year results
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: -1.0%
H: 1.45%
C: -2.17%
report year financial results
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Published: 2023-02-15 (Crawled : 15:00) - biospace.com/
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: 0.13%
H: 0.63%
C: -1.13%
piter-02 treatment trial positive
Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Published: 2023-02-15 (Crawled : 15:00) - globenewswire.com
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: 0.13%
H: 0.63%
C: -1.13%
piter-02 treatment trial positive
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: 1.61%
H: 1.13%
C: -0.9%
report financial results
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab
Published: 2022-10-12 (Crawled : 12:00) - biospace.com/
CHRS | $2.06 3.0% 610K
|
Health Technology
|
| O: -1.15%
H: 1.63%
C: -0.93%
hoice-01 trial positive results publication
Gainers vs Losers
| 82% | 18% |
Top 10 Gainers
AGBA | News | $1.37 242.5% 76M
|
Finance
EGOX | $0.0835 131.94% 160M
|
ZCMD | $2.18 50.35% 24M
|
Commercial Services
CHRO | $1.73 41.22% 46K
|
n/a
RWOD | $10.61 32.68% 5.1M
|
n/a
NVFY | $2.77 31.28% 2.2M
|
Consumer Durables
AULT | $0.3174 31.1% 28M
|
Manufacturing
WISA 4 | $7.11 20.71% 4.7M
|
Electronic Technology
LIFW | News | $0.99 19.26% 800K
|
Administrative and Support and ...
PRTG | $0.285 18.75% 140K
|
Mining, Quarrying, and Oil and ...
Your saved searches
Save your searches and get alerts when important news are released.